EGFR and cancer: The adjuvant chemotherapy was therefore implemented only in the high-risk group which could successfully produce a cancer-free status in a significant proportion of the patients.[22] EGFR Tyrosine Kinase Inhibitors (TKIs) are commonly used adjuvant immunotherapy for patients resistant to chemotherapy and its efficacy in patients harboring EGFR mutations has been extensively studied.